| Specialty Retail Industry | Consumer Discretionary Sector | Dr. Makkapati Satakarni B.E., M.B.A., Ph.D. CEO | XNSE Exchange | Y04527142 CUSIP |
| India Country | 26,015 Employees | 8 Aug 2025 Last Dividend | 10 Feb 2011 Last Split | - IPO Date |
Aurobindo Pharma Limited is a prominent biopharmaceutical company that specializes in the manufacturing of generic formulations and active pharmaceutical ingredients (APIs) for a global market. Founded in 1986, the company has established its headquarters in Hyderabad, India, and extends its reach across several key international markets including the United States of America, Europe, and Puerto Rico. Aurobindo Pharma is dedicated to providing a vast range of pharmaceutical products that cater to various therapeutic areas, thereby playing a pivotal role in enhancing global healthcare.
Aurobindo Pharma offers a diverse portfolio of generic formulations encompassing oral solids, liquids, injectables, and vaccines. The company also produces over-the-counter drugs, ensuring wide accessibility to quality medicines for various health conditions.
The company manufactures a wide array of APIs, providing essential components for many drugs across different therapeutic categories. These include crucial areas such as the central nervous system, cardiovascular diseases, and antibiotics, among others.
Aurobindo develops biosimilars, which are biologically similar products to already approved biological medicines, offering alternatives that can be more cost-effective while maintaining the same efficacy and safety profiles as their reference products.
Dedicated to innovation, Aurobindo Pharma also focuses on the production of biocatalysts, peptides, and hormones, targeting critical therapeutic areas like anti-retrovirals, anti-diabetics, and gastroenterology.
The company is committed to the global fight against HIV, providing antiretroviral drugs to support both adults and children living with HIV. This endeavor represents Aurobindo Pharma’s dedication to addressing global health crises through effective treatments.
Aurobindo Pharma offers project-based chemistry contract services, which encompass a wide range of services from the clinical stage through to manufacturing. This includes managing the entire lifecycle of a drug in the API space, specializing in sterile and non-sterile penicillins, cephalosporins, penems, and non-beta lactams. Through these services, Aurobindo Pharma facilitates the development and production of pharmaceuticals, supporting companies in bringing effective medicines to market.